view-ebook.png

HCC app screenshot-200px.jpg

Download the mobile app (only for registered participants)
if you are registered for this event you have already received an email with all the details and links.

WELCOME MESSAGE

The European Association for the Study of the Liver (EASL) will be delighted to be your hosts at the second EASL HCC Summit, taking place in Geneva, Switzerland on 2-5 February 2017.  Our first summit 2 years ago was a great success, reaching out to both scientists and clinicians with an interest in liver cancer. Following a similar winning formula, we have created a broad and exciting programme, which we hope will be both informative and stimulating.

Covered topics

Basic Science Sessions: Next generation and exome sequencing, Molecular signaling and imaging, Angiogenesis, Cell metabolism, Cell death, Inflammation, Gut microbiome, Genomic instability.

Clinical Sessions: Patient management, Epidemiology, Diagnostic challenges, Surgical and locoregional therapy, Intrahepatic cholangiocarcinoma, Systemic Treatments, Immunotherapy.

Our Basic Science programme on 2nd and 3rd February this year will be centred around ‘The Hallmarks of Cancer’, including talks from eminent scientists in the cancer field, but with a focus on those translational advances most relevant to patients with primary liver cancer. This will be immediately followed on 4th and 5th February by an outstanding Clinical programme, with state of the art talks on the most up to date management of our patients with liver cancer. Aimed at a wider audience, we have no doubt that there will be something for everyone. Participants will be offered the option to attend either programmes or both. There will be the opportunity also to submit abstracts of ongoing research. Some of these will be included in the oral programme, while others will be accepted as e-posters.

We anticipate that this combination of high quality presentations from eminent scientists and clinicians will bring together leading researchers and young investigators with an interest in liver cancer, for a highly interactive for what will be a memorable meeting.

We look forward to welcoming you in Geneva for this major event.

The Scientific Committee

Targeted audience             Why attend?
  • Hepatologists
  • Physicians with interest in liver cancer
  • Basic and translational scientists
  • Clinical researchers
  • Health professionals
  • Young researchers and trainees
 
  • 4 days of cutting edge basic and clinical research on HCC
  • 2 Days entirely dedicated to basic and translational science with 7 sessions covering the latest in research
  • 2 Days of clinical, diagnosis and management of HCC
  • Gather, network and discuss your latest research with renowned scientists and leading experts
Scientific Committee
 

Helen Reeves

United Kingdom

Tom Luedde

Germany

Franco Trevisani

Italy

Alejandro Forner

Spain

 

Key Deadlines
 

Abstract
Submission

28 November 2016

Early
Registration

18 December 2016

Mid
Registration

3 January 2017


Registration
REGISTRATION
Register and book your hotel accommodation now!
Programme
ONLINE PROGRAMME
Abstracts
ABSTRACT SUBMISSION
Abstract submission is now closed.